Company news

Achieve Life Sciences, Inc. news in 2024

Achieve Life Sciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

December 8, 2024

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

December 2, 2024

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

October 15, 2024

Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting

October 9, 2024

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

September 30, 2024

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

August 25, 2024

Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

August 12, 2024

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

July 30, 2024

Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank

July 28, 2024

Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes

May 28, 2024

Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting

May 16, 2024

Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update

May 8, 2024

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

May 5, 2024

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update

March 27, 2024

Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

March 19, 2024

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024

March 13, 2024

Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission

February 28, 2024

Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement

February 28, 2024

Calls in 2024